Table 2 General features of the studies
Studies | Ticagrelor monotherapy in patients with DM | Ticagrelor monotherapy in patients without DM | Participants’ selection | Enrollment period (years) | Year of publication | Bias risk grade |
|---|---|---|---|---|---|---|
Global Leaders [13] | 1332 | 11,351 | randomization | 2013—2015 | 2020 | B |
Twilight [14] | - | - | randomization | 2015—2017 | 2020 | B |
Twilight DM CKD [15] | 2526 | 4309 | randomization | 2015—2019 | 2022 | B |
Tico [16] | 835 | 2221 | randomization | 2015 – 2018 | 2021 | B |
Total No of participants (n) | 4693 | 17,881 | Â | Â | Â | Â |